Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-27T07:08:26.188Z Has data issue: false hasContentIssue false
  • English
  • Français

Does plasma phoenixin level associate with cognition? Comparison between subjective memory complaint, mild cognitive impairment, and mild Alzheimer's disease

Published online by Cambridge University Press:  29 May 2017

Mehmet Yuruyen ,
Gozde Gultekin ,
Gizem Cetiner Batun ,
Hakan Yavuzer ,
Fundan Engin Akcan ,
Alper Doventas  and
Murat Emul
Mehmet Yuruyen
Affiliation:
Department of Internal Medicine, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey
Gozde Gultekin*
Affiliation:
Department of Psychiatry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey
Gizem Cetiner Batun
Affiliation:
Department of Psychiatry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey
Hakan Yavuzer
Affiliation:
Department of Internal Medicine, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey
Fundan Engin Akcan
Affiliation:
Department of Psychiatry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey
Alper Doventas
Affiliation:
Department of Internal Medicine, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey
Murat Emul
Affiliation:
Department of Psychiatry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey
*
Correspondence should be addressed to: Gozde Gultekin, MD, Department of Psychiatry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey. Phone: +90 5379825762. Emails: gozdee_gultekinn@hotmail.com, gozdeegultekinn@gmail.com.
Get access

Abstract

Background:

Alteration in energy expenditure or metabolism is the most accused risk issue for the onset and for the course of neurodegenerative cognitive disorders. Neuropeptides are suggested to be related with learning and memory. Phoenixin (PNX) is the most recently reported neuropeptide and we aimed to compare the plasma level in people with subjective memory complaints, patients with mild cognitive impairment, and mild Alzheimer's disease (AD).

Methods:

Ninety two participants enrolled in the study. After screening tests, all participants were assessed with a neuropsychological battery for further cognitive evaluations. We used ELISA kit to assay the level of Human PNX.

Results:

Patients with AD were significantly older than people in subjective memory complaint group (p = 0.02). There was no significant difference between groups according to gender (p = 0.435). Mean plasma PNX level was not significantly different between groups (p = 0.279). Mean plasma PNX level in MCI group was positively correlated with BMI (r = 0.402 and p = 0.028), serum HDL level (r = 0.454 and p = 0.012), blood systolic pressure (r = 0.428 and p = 0.018) and negatively correlated with logical memory (r=−0.335 and p=0.031). The mean plasma PNX level was positively correlated with immediate recall in subjective memory complaint group (r = 0.417 and p = 0.034).

Conclusion:

This study is the first studying the association of plasma PNX level and cognitive complaints or decline. The knowledge about the role, interaction, and physiological functions of PNX is lacking. Lower plasma PNX level might be important in prodromal stages as MCI and the predictive role of PNX should be investigated in further studies.

Keywords

neuropeptidesphoenixincognitionleptindementiamild cognitive impairmentsubjective memory complaint
Type
Research Article
Information
International Psychogeriatrics , Volume 29 , Issue 9 , September 2017 , pp. 1543 - 1550
Copyright
Copyright © International Psychogeriatric Association 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baranowska-Bik, A. et al. (2015). Plasma leptin levels and free leptin index in women with Alzheimer's disease. Neuropeptides, 52, 1543–1550.Google Scholar
Burke, W. J. et al. (1988). Reliability of the Washington university clinical dementia rating. Archives Neurology, 45, 31–32.Google Scholar
Diano, S. et al. (2006). Ghrelin controls hippocampal spine synapse density and memory performance. Nauture Neuroscience, 9, 381–388.Google Scholar
Ertan, T., Bugay, G. and Eker, E. (2004). The reliability and validity of short form of geriatric depression scale in Turkish elderly population. Poster in 5. National Geropsychiatry Symposium, Istanbul, Turkey. (in Turkish).Google Scholar
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal Psychiatric Research, 12, 189–198.Google Scholar
Golden, C. J. (1978). Stroop Colour And Word Test. Chicago: Stoelting Publishing House.Google Scholar
Greco, S. J. et al. (2010). Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease, 19, 1155–1167.Google Scholar
Gustafson, D. R. et al. (2012). Leptin and dementia over 32 years – the prospective population study of women. Alzheimer's & Dementia, 8, 272–277.Google Scholar
Güngen, C., Ertan, T., Eker, E., Yasar, R. and Engin, F. (2002). The reliability and validity of standardized mini-mental state examination in mild dementia for Turkish population. Turk Psikiyatri Dergisi, 13, 273–281.Google Scholar
Hachinski, V. C., Iliff, L. D. and Zilhka, E. (1975). Cerebral blood flow in dementia. Archives Neurology, 32, 632–637.Google Scholar
Harvey, J. (2010). Leptin: the missing link in Alzheimer disease? Clinical Chemistry, 56, 696–697.Google Scholar
Isaacs, B. and Akhtar, A. J. (1972). The SET test: a rapid test of mental function in older people. Age Aging, 1, 222–226.Google Scholar
Jiang, J. H. et al. (2015a). Effects of phoenixin-14 on anxiolytic-like behavior in mice. Behavioural Brain Research, 286, 39–48.Google Scholar
Jiang, J. H. et al. (2015b). Phoenixin-14 enhances memory and mitigates memory impairment induced by Aβ1-42 and scopolamine in mice. Brain Research, 1629, 298– 308.Google Scholar
Johnston, J. M. et al. (2014). Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Current Alzheimer Research, 11, 165–174.Google Scholar
Karakas, S. (2004). Handbook of Bilnot Battery (in Turkish). Ankara: Dizayn Ofset.Google Scholar
Kojima, M. and Kangawa, K. (2006). Drug insight: the functions of ghrelin and its potential as a multitherapeutic hormone. Nature Clinical Practice Endocrinology & Metabolism, 2, 80–88.Google Scholar
Lieb, W. et al. (2009). Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. The Journal of the American Medical Association, 302, 2565–2572.Google Scholar
Littlejohns, T. J. et al. (2015). Serum leptin and risk of cognitive decline in elderly Italians. Journal of Alzheimer's Disease, 44, 1231–1239.Google Scholar
Liu, X. H., Lee, K. and Herbison, A. E. (2008). Kisspeptin excites gonadotropin-releasing hormone neurons through a phospholipase C/calcium-dependent pathway regulating multiple ion channels. Endocrinology, 149, 4605–4614.Google Scholar
Magalhaes, C. A., Carvalho, M. G., Sousa, L. P., Caramelli, P. and Gomes, K. B. (2015). Leptin in Alzheimer's disease. Clinica Chimica Acta, 450, 162–168.Google Scholar
Maioli, S. et al. (2015). Alterations in brain leptin signaling in spite of unchanged CSF leptin levels in Alzheimer's disease. Aging Cell, 14, 122–129.Google Scholar
McNay, E. C. (2007). Insulin and ghrelin: peripheral hormones modulating memory and hippocampal function. Current Opinion in Pharmacology, 7, 628–632.Google Scholar
Moran, T. H. and Gao, S. (2006). Looking for food in all the right places? Cell Metabolism, 3, 233–234.Google Scholar
O'Neill, D., Gerrard, J., Surmon, D. and Wilcock, G. K. (1995). Variability in scoring the Hachinski Ischaemic score. Age Ageing, 24, 242–246.Google Scholar
Oomura, Y. et al. (2006). Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides, 27, 2738–2749.Google Scholar
Pałasz, A., Rojczyk, E., Bogus, K., Worthington, J. J. and Wiaderkiewicz, R. (2015). The novel neuropeptide phoenixin is highly co-expressed with nesfatin-1 in the rat hypothalamus, an immunohistochemical study. Neuroscience Letter, 592, 17–21.Google Scholar
Pendlebury, S. T., Mariz, J., Bull, L., Mehta, Z. and Rothwell, P. M. (2012). MoCA, ACE-R, and MMSE versus the national ınstitute of neurological disorders and stroke-Canadian stroke network vascular cognitive ımpairment harmonization standards neuropsychological battery after TIA and stroke. Stroke, 43, 464–469.Google Scholar
Pérez-González, R et al. (2014). Leptin gene therapy attenuates neuronal damages evoked by amyloid-β and rescues memory deficits in APP/PS1 mice. Gene Therapy, 21, 298–308.Google Scholar
Rey, A. (1964). L'examen Clinique en Psychologie. Paris: Presses Universitaires de France.Google Scholar
Rigamonti, A. E. et al. (2002). Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. Journal of Endocrinology, 175, R1–R5.Google Scholar
Scarpace, P. J. and Tumer, N. (2001). Peripheral and hypothalamic leptin resistance with age-related obesity. Physiology & Behavior, 74, 721–727.Google Scholar
Sheikh, J. and Yesavage, J. (1986). Geriatric depression scale (GDS); recent evidence and development of a shorter version. In Clinical Gerontology: A Guide to Assessment (pp. 165–173). NewYork: Hawthorne Press.Google Scholar
Signore, A. P., Zhang, F., Weng, Z., Gao, Y. and Chen, J. (2008). Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. Journal of Neurochemistry, 106, 1977–1990.Google Scholar
Sunderland, T. et al. (1989). Clock drawing in Alzheimer's disease. A novel measure of dementia severity. Journal of American Geriatric Society, 37, 725–729.Google Scholar
Teunissen, C. E. et al. (2015). Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. Journal of Alzheimer's Disease, 44, 809–813.Google Scholar
Tezapsidis, N., Smith, M. A. and Ashford, J. W. (2009). Central obesity and increased risk of dementia more than three decades later. Neurology, 72, 1030– 1031.Google Scholar
Utsunomiya, K. et al. (2010). Lack of association between the leptin receptor gene (LEPR) Gln223Arg polymorphism and late-onset Alzheimer disease. Alzheimer Disease and Associated Disorders, 24, 101–113.Google Scholar
Warren, M. W., Hynan, L. S. and Weiner, M. F. (2012). Leptin and cognition. Dementia and Geriatric Cognitive Disorders, 33, 410–415.Google Scholar
Wechsler, D. (1987). Wechsler Memory Scale-Revised Manual. San Antonio, TX: Psychological Corporation.Google Scholar
Yosten, G. L. et al. (2013). A novel reproductive peptide, phoenixin. Journal of Neuroendocrinology, 25, 206–215.Google Scholar
Zeki, A., Hazzouri, A., Haan, M. N., Whitmer, R. A., Yaffe, K. and Neuhaus, J.(2012). Central obesity, leptin and cognitive decline: the Sacramento area Latino study on aging. Dementia and Geriatric Cognitive Disorders, 33, 400–409.Google Scholar